Introduction
============

Micturition involves passive, low pressure filling of the bladder during the urine storage phase whilst voiding requires coordination of detrusor contraction with urinary sphincter relaxation. The process is controlled by a complex neural control system, involving interaction between the sympathetic, parasympathetic and somatic nervous systems ([@r1]). Disturbance to the normal micturition process as a result of neurological damage or disease is known as neurogenic bladder (NGB). The term NGB encompasses a breadth of neurological etiologies including spina bifida, stroke, spinal cord injuries (SCI), multiple sclerosis (MS), and Parkinson's disease (PD) ([@r2]). Although patients share the same diagnosis of NGB, they are notably unique in urological symptom and risk profile due to the difference in underlying condition (including stage and severity of disease) and location of neurological lesion.

This considerable heterogeneity compounds the availability of a single optimal medical therapy, meaning that treatments are often wide-ranging and individualized to the particular patient ([@r3]). Myriad treatment modalities can be employed including behavioral therapies, oral pharmacotherapy, catheterization and surgery. Four key aims outlined by the European Association of Urology (EAU) that are of paramount importance when selecting treatments are protection of the upper urinary tract, improvement of urinary continence, restoration of the lower urinary tract function and improvement of patient quality of life (QoL) ([@r4]).

Despite the availability of clinical guidelines, a survey conducted in the Netherlands found that "*18% of urologists used the EAU guidelines on NGB frequently*, *35% did so occasionally and 47% did not use them at all*" ([@r5]). This systematic review (SR) aims to collate evidence on the management strategies that are employed in the real world and determine whether practices are in concordance with prominent NGB clinical guidelines. This research can act as an important preliminary step in influencing future guideline recommendations to reflect what is working for physicians in the real world. This research also demonstrates how prescribing patterns in NGB may have changed over time. This article aims to describe the treatment patterns and management strategies of NGB in the real word.

Methods
=======

Eligibility criteria
--------------------

I.  Patients with any neurological condition, e.g., spina bifida, stroke, SCI, MS, PD;

II. Studies that measure treatment use e.g., percentage use, duration of use, treatment switching, combination use;

III. Real world studies, including both retrospective or prospective: cohort, case-control, cross-sectional and chart review.

During the pilot search, no studies were retrieved that focused solely on adults therefore the search was expanded to include subjects of any age.

Search strategy
---------------

This SR was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines ([*Figure 1*](#f1){ref-type="fig"}) ([@r6]).

![Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.](tau-06-06-1175-f1){#f1}

A search was run on 15th February 2017 using a combination of free-text words and medical subject headings in MEDLINE^®^, and EMBASE^®^ ([*Table S1*](#tS.1){ref-type="table"}). Limits were applied for studies published between the years of 1996--2017. Eligibility assessment was conducted in two stages. In the first stage, an independent reviewer (Ashley Jaggi) screened titles and abstracts for alignment with pre-defined inclusion and exclusion criteria ([*Table 1*](#t1){ref-type="table"}). Ten percent of included papers were cross-examined by a second independent (Francis Fatoye) reviewer. In the second stage, full versions of the included texts, acquiescent with inclusion criteria, were screened by both reviewers. Any disagreements were mediated by discussion.

###### Inclusion and exclusion criteria

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criteria
     Inclusion criteria
        Published in English
        Includes human subjects
        Reporting the treatment patterns/use in NGB
        Conducted in a real world setting
     Exclusion criteria
        Non-English publications
        *In vitro*, pre-clinical or animal studies
        Randomized controlled trials, SRs, case-report/series, editorials, questionnaires, letters, commentaries, legal cases, newspaper articles or patient education materials
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NGB, neurogenic bladder; SRs, systematic reviews.

Data collection and extraction
------------------------------

Information on the study design, patient characteristics, and treatments in NGB was extracted using a piloted data extraction form.

Summary measures
----------------

Treatment patterns were descriptively summarized using narrative review. Percentage of treatment use was summarized using ranges.

Results
=======

A total of 116 publications were yielded. After screening titles and abstracts and removing additional duplicates (ProQuest Dialog^®^ removes most duplicates), 10 articles were retrieved, and the full texts were reviewed. Based on full text review, five papers were excluded for reasons according to the study protocol. A total of eight papers were included for analysis. Three papers were obtained from hand searching ([@r7]-[@r14]).

Study and patient characteristics
---------------------------------

Overall, there were 47,706 patients with NGB, of these, 43.8% were male and the mean age was 42.8. The majority of included patients \[46,271\] were from two studies. Despite being published at separate times (2009 and 2011), these studies included the same cohort of patients (using the same inclusion criteria and database). Patients included in these studies had mixed underlying neurological conditions including MS, SCI, PD, paralytic syndrome, cerebral palsy and spina bifida. What differentiates the two studies is the 2011 study identified separate sub-cohorts for SCI and MS, including 4,168 and 9,315 patients respectively. Most of the included studies (62.5%) focused on patients with SCI (or included a subgroup), at various levels of neurological injury and varied time since injury. Across the studies, there were a total of 5,182 patients with SCI. One study focused on spina bifida patients, including 421 individuals. The earliest period of data collection began in 1984 and the most recent ended in 2007 ([*Table 2*](#t2){ref-type="table"}).

###### Summary of study and patient characteristics of included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                 Data collection period                                     Study design                      Location   Patient sample characteristics                                                                                                                                                                                                                                                                                                                                   Neurological condition and severity
  ----------------------------------------------------- ---------------------------------------------------------- --------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anson \[1996\]                                        Not reported                                               Prospective (longitudinal)        USA        348 individuals, 33% aged over 18, mean age: 36.6, 82% male and 18% female, 80.2% Caucasian                                                                                                                                                                                                                                                                      SCI: C0--C4: 19.7%, C5--C8: 36.2%, T1--T11: 29.4%, T12--S5: 14.7%; years since injury: 1--2 years: 26%, 3--5 years: 25.2%, 6--10 years: 29.3%, 11--15 years: 12%, 15+ years: 8%

  Chia-Cheng \[2012\]                                   2006--2008                                                 Retrospective (cross-sectional)   Taiwan     165 patients, mean age: 54, 64% male and 46% female                                                                                                                                                                                                                                                                                                              Patients with emergency department visits or hospitalizations for SCI

  Drake \[2005\]                                        1990--1996                                                 Prospective (longitudinal)        UK         196 individuals, aged 15--55, mean age: 57.4, 86% male and 24% female                                                                                                                                                                                                                                                                                            SCI for at least 20 years; level of injury: paraplegics with complete SCI (Frankel grade A, B, or C): 49%; tetraplegics with complete SCI (Frankel grade A, B, or C): 31.1%; incomplete SCI (Frankel grade E): 18.9%; mean years since injury: 33.26

  El-Masri \[2012\]                                     From 1984, with follow up ranging between 8 and 21 years   Retrospective (longitudinal)      UK         119 individuals, aged 16--63, mean age: 29, 83.2% males, 16.8% females                                                                                                                                                                                                                                                                                           SCI: paraplegic (two had S3 sacral lesion): 37.3%; tetraplegic: 27%; Frankel grade A: 34%; Frankel grade B: 4.3%; Frankel grade C: 7.7%; Frankel grade D: 18.4%; mean years since injury: 29

  Lemelle \[2006\]                                      2003--2004                                                 Retrospective (longitudinal)      France     421 individuals, aged 10--47.5, mean age: 22.1, 140 aged 10--18 and 281 aged over 18; 55% male and 45% female                                                                                                                                                                                                                                                    Spina bifida (myelomeningocele at the neonatal period, which was treated surgically); ability to move: walk with minor aid: 63%; walk with walking appliance: 3%; wheelchair outside + walk at home: 8%; wheelchair most of time: 26%

  Manack \[2011\] & Manack \[2009\] (NGB cohort only)   April 1, 2002--March 31, 2007                              Retrospective (longitudinal)      USA        46,271 individuals in NGB cohort, 9,315 individuals in MS, 4,168 individuals in SCI, aged 0--60+, mean age of NGB cohort was 62.5 years, mean ages in the MS and SCI subcohorts, 53.2 and 61.9 years respectively. 43.6% males and 57.4% females in NGB cohort, 31.3% male and 79.7% female, 41.9% male and 59.1% female in MS and SCI subcohorts respectively   MS, \[SCI (including paraplegia, quadriplegia, tetraplegia), spina bifida, Parkinson's disease, cerebral palsy, hemiplegia/hemiparesis, late effects of stroke, other paralytic syndromes, and neoplasm of the spinal cord\]

  Weld \[2000\]                                         Years not reported;\                                       Retrospective (longitudinal)      USA        316 individuals, mean age: 38 years, 99% male and 1% females                                                                                                                                                                                                                                                                                                     SCI: injury completeness: complete: 14.2%, incomplete: 85.8%; injury level: suprasacral: 85.1%, sacral: 14.9%; mean years since injury: 18.3 years
                                                        follow up: 18.3 years since injury                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C, cervical nerves; T, thoracic nerves; SCI, spinal cord injuries; MS, multiple sclerosis; NGB, neurogenic bladder.

Treatment patterns
------------------

### Oral pharmacotherapy

Five out of the eight included studies included data on the use of oral pharmacotherapy. Three studies included information on antimuscarinic drug use, which spanned between 12.6--86.7%. Results from two studies demonstrated a range of 12.6--39% patients using oxybutynin.

The lowest recorded antimuscarinic drug use was reported by Lemelle *et al.*, where 12.6% of spina bifida patients used oxybutynin regularly. The percentage of patients receiving antimuscarinics was almost double in the study by Chia-Cheng *et al.*, where it was used by 26% of SCI patients with neurogenic detrusor overactivity (NDO). Manack *et al.* \[2011\] reported much higher percentages, with 71.5% of patients in the NGB cohort, 80.9% in the SCI cohort and 86.7% in the MS cohort using this treatment. A prescription of an antimuscarinic drug (rather than any form of bladder management method), was one way in which a patient could be included into the study by Manack *et al.* \[2011\], which could explain why percentage use was higher in this study, than other studies in this review. The highest use of oxybutynin of all publications was also recorded in this study (39%), followed by tolerodine (36.9%). El-Masri *et al.* mention that antimuscarinics were administered to those with NDO, but percentage use is not delineated.

El-Masri *et al.* and Chia-Cheng *et al.* reported the use of alpha-blockers; however, neither of the authors communicated the names of drugs. In the study by Chia-Cheng *et al.*, the most prevalent drugs amongst SCI patients with NDO were alpha-blockers, used by 33% of individuals. Alpha-blockers were administered to SCI patients with marked bladder outlet obstruction (BOO) in the study by El-Masri *et al.*, but as with antimuscarinic use, percentage use is not described.

The study by Chia-Cheng *et al.* was the only one to mention use of cholinergics, where it was used by 15% of SCI patients with NDO.

### Patterns of use with oral pharmacotherapy

Manack *et al.* \[2011\] provides information on patterns of oral drug use, which is not available from the other studies. A total of 7,782 continued on an OAB drug, 10,110 discontinued and did not start, and a further 9,030 stopped and restarted. The average length of time on drug was 209.1 days for the MS subcohort and 195.5 days for the SCI cohort.

### Catheterization

Urinary catheter use varied substantially. Intermittent catheterization (IC) use was reported in six studies, with a range between 0--84%. Indwelling catheterization (IDC) \[both indwelling urethral catheterization (IDUC) and indwelling suprapubic catheterization (SPC)\] was reported in four studies, with a range of 0% to 100%.

Chia-Cheng *et al.* reported that catheterization was used by 67% of patients with NDO as a consequence of SCI, however it is unclear whether catheterization refers to IC or IDC

### IC

Lemelle *et al.* reported that 71.3% patients with spina bifida were using IC. Anson *et al.* and Weld *et al.* reported much smaller percentages in post-acute phase SCI, with 30.5% and 29.1% respectively.

When considering studies with observations at multiple time points, El-Masri *et al.* reported 27% of SCI patients using assisted IC immediately before admission to the hospital; however, no patients utilized this method upon admission. During hospitalization, 4-hourly IC was the most utilized method, with 84% of patients using it at least once. This is the highest report of IC use from all publications. This markedly declined to 15.1% patients at discharge from hospital. In contrast to El-Masri *et al.*, the use of IC increased by 10.2% in the study by Drake *et al.*; from 3.6% SCI patients in 1990 to 13.8% in 1996.

The difference in IC use between these two studies could be attributable to the varied follow-up. In Drake *et al.*, changes take place over six years whereas follow up in the study by El-Masri *et al.* ranged between 8 and 21 years (mean 17.7).

### IDC

Weld *et al.* reported 36.1% post-acute SCI patients that utilized IDUC and 11.4% patients had a SPC fitted. In the study by Anson *et al.*, much lower percentages were reported, with 9.8% that used IDUC and 3.2% that used SPC. The lowest recorded use of SPC use amongst the publications was one spina bifida patient in the study by Lemelle *et al.*

Studies with multiple observations seemed to paint a heterogeneous picture of IDC use. Overall, IDUC use substantially decreased (by 60.6%) in SCI patients, throughout the duration of the study by El-Masri *et al.*, but the general trend was not a linear decline. SPC use decreased at a much lower rate (0.8%) from hospitalization to discharge. In contrast to this, the number of SCI patients utilizing IDUC increased by 1.6% during the study by Drake *et al.*, and SPC use increased by 7.2%.

In the study by El-Masri *et al.*, 69% were managed with IDUC before admission to hospital and this increased to all patients upon admission; 21% of patients utilized this method at least once during hospitalization. After discharge, 8.4% patients remained with IDUC. In the study by Drake *et al.*, 12.2% had IDUC in 1990 and this increased to 13.8% in 1996.

The first recorded use of SPC was in the study by El-Masri *et al.* was during hospitalization, where 5% of patients utilized this method. After discharge, it was used by 4.2% of patients. Only 2% utilized SPC at study entry in the study by Drake *et al.*, but this increased at a much higher rate than IDUC use, with 9.2% of patients utilizing this method at study end.

### Reflex voiding (RV)

RV methods can include bladder expression (Credé), straining (Valsalva) and triggered RV ([@r4]). In this SR, RV use was reported in four studies, varying from 2.5% to 53.1%.

RV methods are used by 25% of SCI patients in the study by Anson *et al.* and 23% SCI patients in the study by Weld *et al.* Although these percentages are close in range, they cannot be directly compared as Anson *et al.* fail to provide a definition of RV. Weld *et al.* defines spontaneous voiding as "*reflexive voiding with a post*-*void residual urine of less than 100 cc and a voiding pressure of less than 40 cm*".

In the study by Drake *et al.*, RV was defined as "*leaving a post void residual \<10% and with no upper tract dilation, with or without prior sphincterotomy or urethral stent*". Use decreased by 11.8% during the study period, from 53.1% to 41.3%, but it remained the most used method within the study.

El-Masri *et al.* did not specifically define RV. A small number of patients (2.5%) were managed with RV prior to admission and during hospitalization it was used by 16.8% individuals. It was the most common form of bladder management after patients were discharged from the hospital, where it was utilized by 49.8% patients.

In the study by Drake *et al.*, straining methods (defined as either Credé or Valsalva) decreased by 8.2%, from 19.4% to 11.2%. A much lower percentage (2.6%) of patients used expression techniques (Credé) at the end of the study by El-Masri *et al.*

### Surgery

Two authors report use of surgery to manage bladder symptoms. Manack *et al.* \[2009\] reports particularly low numbers of bladder augmentation and interstim therapy (0.2% and 0.4% respectively) in NGB patients. This is in contrast to Lemelle *et al.*, where the majority of spina bifida patients (55%) were surgically treated. Of these patients, 21.3% underwent bladder neck surgery, without bladder augmentation (with or without continent diversion), 36% patients underwent intestinal bladder augmentation (with or without bladder neck procedure) and 28.3% patients underwent intestinal bladder augmentation in addition to Mitrofanoff (with or without bladder neck procedure).

### Other management methods

In the study by Lemelle *et al.*, 8.3% of people used pads and 1% of patients used an uriseath.

### Combination use

#### Combinations of oral pharmacotherapy

Manack *et al.* \[2011\] reported 8.7% of patients on a combination of two or more antimuscarinic drugs; 8.3% were on two drugs, 0.4% were on three drugs and a negligible amount were on four or more drugs. A similar pattern was seen in the MS and SCI subcohorts; 9.5% patients in the MS subcohort were on a combination of two or more antimuscarinics, a further 9% were on two drugs, 0.5% were on three drugs and only two patients were on four or more drugs. When considering the SCI cohort, 9.2% patients were on a combination of two or more antimuscarinics, 8.9% were on two drugs, 0.3% were on three drugs and no patients were on four of more drugs.

A combination of alpha-blockers and antimuscarinics were given to those with detrusor sphincter dyssynergia (DSD) and autonomic dyssynergia in the study by El-Masri *et al.* Percentages of combination use were not reported.

#### Combination of a therapy with catheterization

Lemelle *et al.* states that 12.6% spina bifida patients regularly utilized IC in combination with oxybutynin. 90% of patients used IC in addition to surgery, including 61% through a continent neoconduit and 39% on abdominal wall.

In the study by Anson *et al.*, 11.5% patients were on a combination of IC and reflex. There is also a report of 3.7% of patients on some combination of treatments between IC, reflex, IDUC, SPC and self-voiding, but actual combinations are not provided.

#### Combination of surgical procedures and bladder neck injections

Lemelle *et al.* reports 39% of patients undergoing a combination of surgical procedures to achieve reservoir and neck management in spina bifida patients. The most popular combination of procedures is intestinal bladder augmentation + Mitrofanoff principle + neck closure.

#### Switching

Weld *et al.* mentions that most post-acute SCI patients switched bladder management methods over the course of the study period; with the most prevalent change being from IC to IDUC (percentage is not provided); 14.3% of patients in the study by Drake *et al.*, and one patient in the study by El-Masri *et al.* also made this particular switch of treatments.

As in the study by Weld *et al.*, most patients in the study by Drake *et al.* switched from their original mode of management (62.8%). However, the most prevalent change in this study was straining to IC (28.9%). The most used method in 1990 was RV, and this remained the case in 1996, despite 24% switching to an alternative form of treatment.

El-Masri *et al.* also showed a large proportion of patients (39.5%) that switched treatments during hospitalization. In contrast to both Weld *et al.* and Drake *et al.*, the most prevalent switch was IC to sphincterotomy and IDUC to IC.

Discussion
==========

Selecting optimal treatments and employing appropriate management strategies for NGB patients is integral to improving patients' bladder symptoms and improving QoL. With passing time, clinicians have moved away from techniques associated with higher rates of complications and mortality, thus in recent years, the survival chances of NGB patients have substantially improved ([@r15]). This SR revealed that numerous treatments have been used to manage NGB throughout the years and there has been a large variance in their use.

The most popular oral pharmacotherapy in this SR were antimuscarinics, which are cited as first line therapy for NDO in the National Institute for Health and Care Excellence (NICE), EAU and International Consultations on Incontinence (ICI) guidelines ([@r4],[@r16],[@r17]). This conclusion should be viewed with some caution, as many studies in this review did not measure the use of oral pharmacotherapy, instead focusing their attention on other methods of bladder management. It is however well known that NDO is frequently observed in SCI (which 62.5% of included studies focused on) and antimuscarinics have acted as the primary mode of treatment for a number of years ([@r18]).

In the study by Manack *et al.* \[2011\], some patients used a combination of two or more antimuscarinics. Based on evidence from a few small clinical trials, the EAU provide a grade B recommendation, asking physicians to consider a combination of antimuscarinic agents ([@r4],[@r19]-[@r21]). Other available guidelines do not provide graded recommendations on combination antimuscarinic use.

Invasive forms of management such as bladder augmentation are only employed once more conservative measures have been exhausted. A minority of spina bifida patients do not respond well to conservative treatments thus must undergo surgery to improve bladder functionality ([@r22]). Conversely, the one study included in this SR, focusing on spina bifida, reported that the majority of patients underwent surgery. This may be due to a high severity of incontinence in this sample, higher incidence of refractory NGB or a less conservative attitude of physicians towards surgery in France between 2003--2004 (the study period).

Many of the studies in this SR have early periods of data collection therefore, it is perhaps comprehensible that some practices deviated from what is currently considered safe and effective. One example of such variance is the use of the Credé and Valsalva manoeuvres in studies that collected data in the 1980's and 1990's ([@r7],[@r11]). In current guidelines, these techniques are contraindicated due to complications including epidydymoorchitis and haemorrhoids ([@r4],[@r17],[@r23]).

IDC was also widely used (up to 100%) despite the fact that this type of catheterization is associated with an increased risk of urinary tract infection (UTI), and more serious conditions such as bladder cancer ([@r4],[@r16]). It is important to remember however, that SCI can result in limited manual dexterity (e.g., in the case of tetraplegia), impeding the ability of intermittent self-catheterization (ICS) ([@r24]). The current NICE guidelines recognise that in some instances the choice of management technique is limited by what the patient can manage ([@r16]). Furthermore, the latest ICI guidelines suggest that assigning causation of urinary tract damage to IDC may not be accurate, as it is often utilized in patients in whom urinary tract damage has already occurred. Drake sugested that IDC may in fact be protective for the upper urinary tract ([@r25]). Although SPC is generally prefered over IDUC, it was used at a much lower rate. This could possibly be because placement of SPC is a more invasive procedure than IDUC ([@r17]).

This review had a global geographical scope, thus one may assume that the management methods employed reflect the healthcare system and national guidelines in which the study was conducted. At present, the American Urology Association (AUA) lacks any specific guidelines for the management of NGB. High antimuscarinic use in the two U.S. studies by Manack *et al.* are in line with other internationally available guidelines, where antimuscarinics are first line therapy for patients with NDO ([@r4],[@r16],[@r17]). In the study by Chia-Cheng *et al.*, conducted in Taiwan, alpha-blockers were the main method of management for NDO, despite Taiwanese NGB guidelines stating there is strong evidence to support the use of antimuscarinics in NDO ([@r26]). Their use may indicate patients had retention symptoms, in conjunction to NDO. Alternatively, several small clinical trials have demonstrated efficacy of alpha-blockers in NDO, which could indicate that clinicians in the real world are making choices in divergence from guideline recommendations ([@r27],[@r28]). This notion correlates with results from a survey conducted by Rikken *et al.*, which showed that urologists did not follow guideline recommendations meticulously. Nevertheless, this survey also found that despite not adhering to guidelines, urologists still tended to make choices in accordance with recommendations ([@r5]).

Three studies demonstrated notable treatment switching, which could be indicative of the dynamic progression of NGB. Duration of time since injury in SCI can have an impact on bladder compliance that can consequently influence changes in the choice of management strategy ([@r15]). Alternatively, treatment switching may demonstrate that a trial and error approach is necessary to establish an optimal treatment regime ([@r29]). A number of factors influence the initial choice of management method, including type of NGB, sex, age, hand dexterity and healthcare access ([@r30]). In the study by Drake *et al.*, reasons for switching treatments pertained to complications such as functional decline and UTI's ([@r7]). Some patients included in this review made their own treatment choices, indicating that individual preference also plays a large role ([@r7],[@r11],[@r12]). Current guidelines promote active dialogue between the physician and patient/their carer. In particular, NICE guidelines make specific recommendations for education of patients and their carers on the advantages and disadvantages of all available options so they are able to make informed management decisions ([@r16],[@r31]).

Methodological limitations
==========================

The sensitivity of the search strategy could have been increased by including search terms for underlying neurological conditions. Additionally, publication bias and inclusion of mixed study designs could have affected the reliability of results.

Conclusions
===========

Many treatments reported in this review are in line with current guideline recommendations; however, possibly due to the early years of data collection, some divergence was also evident. Due to the small number of studies, varied patient baseline characteristics, and selectiveness in the type of treatments and bladder management methods reported, a representative picture of real world treatment patterns in NGB could not be fully elucidated. Large epidemiological studies using electronic medical records (EMRs) are necessary to advance our understanding in how management strategies have changed over time, understand how patients are managed in current practice, and determine how well patterns relate to clinical guidelines.

###### Search performed in ProQuest Dialog^®^

  Set   Searched for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Results
  ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  S5    \[(S1 AND S2) AND S3\] and \[pd (19960101-20171231)\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     116^\#^
  S4    (S1 AND S2) AND S3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        128^\#^
  S3    {(treatment pattern\*) OR \[standard near/2 (treatment OR therapy OR care)\]} OR MESH.EXACT.EXPLODE ("Standard of Care") OR EMB.EXACT.EXPLODE ("health care quality") OR EMB.EXACT.EXPLODE ("health care utilization")                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    870,350\*
  S2    \[(epidemiolog\* stud\*) OR (case control) OR \[(cohort NEAR/1 (stud\* OR analy\*)\] OR (observational stud\*) OR (longitudinal) OR \[(retrospective OR prospective) near/3 (stud\* OR analy\*)\] OR \[(cross sectional) OR (chart review) OR (medical record review)\] OR EMB.EXACT ("epidemiology") OR EMB.EXACT.EXPLODE ("case control study") OR EMB.EXACT.EXPLODE ("prospective study") OR EMB.EXACT.EXPLODE ("cross-sectional study") or EMB.EXACT.EXPLODE ("cohort analysis") OR EMB.EXACT.EXPLODE ("observational study") OR EMB.EXACT.EXPLODE ("longitudinal study") OR EMB.EXACT.EXPLODE ("retrospective study") OR EMB.EXACT.EXPLODE ("medical record review") OR MESH.EXACT.EXPLODE ("Epidemiologic Studies") OR MESH.EXACT.EXPLODE ("Observational Study")   7,643,028\*
  S1    ti, ab, if {\[(bladder OR detrusor) near/3 dyssynergia\] OR (neurogenic near/3 detrusor near/3 overactiv\*) OR (neurogenic OR neuropathic) near/3 bladder)} OR EMB.EXACT.EXPLODE ("neurogenic bladder") OR MESH.EXACT.EXPLODE ("Urinary Bladder, Neurogenic")                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             20,227\*

\*, duplicates are removed from the search, but included in the result count. ^\#^, duplicates are removed from the search and from the result count.
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